Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?
Expert Review of Clinical Pharmacology · 03.07.2023 · 16 (7) · 623-630
DOI: 10.1080/17512433.2023.2233891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 12.07.2023. Verfasst von Anastasios Lymperopoulos. Beteiligte Einrichtung: Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University Barry and J…. Hauptthemen laut MEDLINE: Cyclic AMP, Heart Failure. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Heart, Lung, and Blood Institute.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
INTRODUCTION: Cyclic 3', 5'-adenosine monophosphate (cAMP) is a major signaling hub in cardiac physiology. Although cAMP signaling has been extensively studied in cardiac cells and animal models of heart failure (HF), not much is known about its actual amount present inside human failing or non-failing cardiomyocytes. Since many drugs used in HF work via cAMP, it is crucial to determine the status of its intracellular levels in failing vs. normal human hearts. AREAS COVERED: Only studies performed on explanted/excised cardiac tissues from patients were examined. Studies that contained no data from human hearts or no data on cAMP levels per se were excluded from this perspective's analysis. EXPERT OPINION: Currently, there is no consensus on the status of cAMP levels in human failing vs. non-failing hearts. Several studies on animal models may suggest maladaptive (e.g. pro-apoptotic) effects of cAMP on HF, advocating for cAMP lowering for therapy, but human studies almost universally indicate that myocardial cAMP levels are deficient in human failing hearts. It is the expert opinion of this perspective that intracellular cAMP levels are too low in human failing hearts, contributing to the disease. Strategies to increase (restore), not decrease, these levels should be pursued in human HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University Barry and Judy Silverman College of Pharmacy, Fort Lauderdale, FL, USA.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- National Heart, Lung, and Blood Institute
Zitieren
APA
Lymperopoulos, A. (2023). Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?. Expert Review of Clinical Pharmacology, 16(7), 623-630. https://doi.org/10.1080/17512433.2023.2233891
Vancouver
Lymperopoulos A. Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?. Expert Review of Clinical Pharmacology. 2023;16(7):623-630. doi:10.1080/17512433.2023.2233891
BibTeX
@article{Lymperopoulos2023,
author = {Lymperopoulos, Anastasios},
title = {Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
volume = {16},
number = {7},
pages = {623--630},
doi = {10.1080/17512433.2023.2233891}
}
EUVIMED